Cancer: The effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation

Current Opinion in HIV and AIDS

Volumn 4, Issue 3, 2009, Pages 183-187

  Grulich, Andrew E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer; HIV; Immune deficiency; Organ transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANUS CANCER; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; MORBIDITY; MORTALITY; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UTERINE CERVIX CANCER; INCIDENCE; METHODOLOGY; TIME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; INCIDENCE; NEOPLASMS; TIME FACTORS;

EID: 67651151187     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328329c5b2     Document Type: Review

References (43)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. This meta-analysis of population-based studies of cancer risk in people with HIV/AIDS and solid organ transplant recipients reported strikingly similar patterns of cancer risk in the two populations, strongly suggesting that immune deficiency was related to a wide range of mainly infection-related cancers.
2. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
3. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. Large-scale follow-up study of cancer occurrence in over 50 000 HIV-infected patients.
4. Vajdic CM, McDonald SP, McCredie MRE, et al. Increased risk of cancer in patients with end-stage kidney disease, prior to renal replacement therapy, on dialysis and after transplantation. JAMA 2006; 296:2823-2831.
5. Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43:2117-2123. Comparison of cancer occurrence in 8074 people with HIV with 2875 organ transplant recipients.
6. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
7. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
8. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
9. Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS 2001; 15:629-633. (Pubitemid 32281359)
10. Franceschi S, Dal Maso L, Pezzotti P, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr 2003; 34:84-90.
11. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39:1380-1384.
12. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. Data linkage study on 57 350 people diagnosed with HIV in the United States. Reported increasing incidence of Hodgkin's disease and liver cancer in the era of HAART.
13. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804. In this cohort study of people with HIV, the incidence of Kaposi's sarcoma declined dramatically, to about 5% of original levels, within 6-12 months of initiation of HAART.
14. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000; 14:987-993. (Pubitemid 30336059)
15. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART (Strategies for Management of Anti- Retroviral Therapy) study. AIDS 2007; 21:1957-1963. This paper presents data on cancer occurrence in a randomized controlled trial of continuous versus intermittent ART. Incidence of AIDS-defining cancers was lower in those receiving continuous ART.
16. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14:133-140. (Pubitemid 30116438)
17. Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999; 21 (S1):S27-S30. (Pubitemid 29357645)
18. Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-2734. (Pubitemid 30770367)
19. Tirelli U, Spina M, Gaidano G, et al. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000; 14:1675-1688. (Pubitemid 30695224)
20. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
21. Bonnet F, Balestre E, Thiébaut R, et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis 2006; 42:411-417. (Pubitemid 43122322)
22. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177-2183. (Pubitemid 41095153)
23. Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic nonHodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003; 103:142-144. (Pubitemid 35424220)
24. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306. This Swiss cohort study with individual patient data demonstrated that the incidence of NHL drops rapidly, to about 10-20% of initial levels, within 12 months of ART initiation.
25. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIVinfected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-3412.
26. Bower M, Powles T, Nelson M, et al. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 2006; 98:1088-1091. (Pubitemid 44288157)
27. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106:128-135. (Pubitemid 43032557)
28. Haldorsen IS, Kråkenes J, Goplen AK, et al. AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer 2008; 8:225.
29. Barclay LR, Buskin SE, Kahle EM, Aboulafia DM. Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma 2007; 7:272-279. (Pubitemid 46408191)
30. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972. Among AIDS-defining cancers, Burkitt lymphoma and cervical cancer were not associated with CD4 cell count at AIDS diagnosis.
31. Hawes SE, Critchlow CW, Sow PS, et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst 2006; 98:100-109.
32. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48:491-499. In this prospective cohort of homosexual men, anal cancer incidence increased markedly in the HAART era.
33. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153. Data linkage study of cancer occurrence among people with AIDS in California. Anal cancer incidence increased in the era of HAART, and liver cancer was negatively associated with HAART use. (Pubitemid 47233717)
34. Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314-320. (Pubitemid 40578072)
35. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211. Cohort study of cancer occurrence in 86 322 HIV-infected patients included in the French Hospital Database on HIV. Anal cancer incidence increased markedly in the HAART era.
36. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 15:1563-1565.
37. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 18:2135-2141. In this nested case-control study within the Swiss HIV cohort study, risk of liver cancer was raised in those with a lower recent CD4 cell count, suggesting that this cancer is associated with immune deficiency.
38. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-1388. (Pubitemid 46622002)
39. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-213. In this data linkage study of 397 927 people with AIDS in the United States, risk of lung cancer was increased, but was not associated with CD4 cell count at AIDS. Under plausible smoking assumptions, lung cancer incidence was higher than predicted, suggesting that immune deficiency may have a direct effect.
40. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110. (Pubitemid 46984625)
41. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. A cohort study of people beginning ART. Risk of non AIDS-defining malignancy increased with declining CD4 cell count. (Pubitemid 351563833)
42. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749. (Pubitemid 43884302)
43. Monforte A, Abrams D, Pradier C, et al. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153. In this large cohort study based in Europe, the United States and Australia, increasing immune deficiency was associated with an increasing risk of death from AIDS-defining and non-AIDS-defining cancer.